SavedAdd your journal

Journals / Sakarya University Journal of Science / 2026 / Volume: 30 Issue: 5

Comparative in Silico Toxicological Assessment of 16 Selective COX-2 Inhibitors (Coxibs) Using Multi-Platform Predictive Models

Ahmet Ali Berber(CANAKKALE ONSEKIZ MART UNIVERSITY)0000-0002-2036-6929
Sinem Öztürk(CANAKKALE ONSEKIZ MART UNIVERSITY)0009-0007-3458-4912
Pages
—
Publication Date
2026-10-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results indicated that while widely used agents like Celecoxib and Etoricoxib exhibit safer profiles, compounds such as Lumiracoxib and NS-398 possess significant carcinogenic and mutagenic potential.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) offer reduced gastrointestinal toxicity compared to traditional non-steroidal anti-inflammatory drugs (NSAIDs), yet their safety remains controversial as evidenced by several market withdrawals due to severe cardiovascular and hepatic risks.
📊
Key Findings & Data:This study systematically evaluated 16 human and veterinary coxib compounds for mutagenicity, carcinogenicity, micronucleus activity, and hepatotoxicity through a multi-platform in silico approach using VEGA-QSAR, ToxTree, and T.E.S.T. software.
💡
Conclusion & Impact:The results indicated that while widely used agents like Celecoxib and Etoricoxib exhibit safer profiles, compounds such as Lumiracoxib and NS-398 possess significant carcinogenic and mutagenic potential.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Coxibs · Computational toxicology · QSAR

Abstract

Selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) offer reduced gastrointestinal toxicity compared to traditional non-steroidal anti-inflammatory drugs (NSAIDs), yet their safety remains controversial as evidenced by several market withdrawals due to severe cardiovascular and hepatic risks. This study systematically evaluated 16 human and veterinary coxib compounds for mutagenicity, carcinogenicity, micronucleus activity, and hepatotoxicity through a multi-platform in silico approach using VEGA-QSAR, ToxTree, and T.E.S.T. software. The results indicated that while widely used agents like Celecoxib and Etoricoxib exhibit safer profiles, compounds such as Lumiracoxib and NS-398 possess significant carcinogenic and mutagenic potential. Notably, high-reliability hepatotoxicity alerts were identified for several veterinary-grade coxibs, raising significant public health concerns regarding drug residues in the equine-derived food chain and potential human exposure. Discrepancies observed between different predictive models highlight the limitations of individual algorithms and underscore the necessity of a consensus approach to improve the robustness of risk evaluations. This study provides an essential foundational framework for the safety assessment of coxib derivatives and emphasizes the critical importance of validating in silico alerts with targeted in vivo research, particularly in the context of food safety and drug residue management.

🔖

Cite This Article

Berber, A. A., Öztürk, S. (2026). Comparative in Silico Toxicological Assessment of 16 Selective COX-2 Inhibitors (Coxibs) Using Multi-Platform Predictive Models. Sakarya University Journal of Science, Volume: 30 Issue: 5. https://doi.org/10.16984/saufenbilder.1867893

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (95)

  1. A. J. Hui, R. W. Leong, and F. K. L. Chan, "Gastric Ulcer," in Encyclopedia of Gastroenterology, L. R. Johnson, Ed., New York, NY, USA: Elsevier, pp. 157–162, 2004. doi:10.1016/B0-12-386860-2/00311-7.
  2. C. J. Smith et al., "Pharmacological analysis of cyclooxygenase-1 in inflammation," Proc. Natl. Acad. Sci. U.S.A., vol. 95, no. 22, pp. 13313–13318, Oct. 1998, doi: 10.1073/pnas.95.22.13313.
  3. F. W. Wiese, P. A. Thompson, and F. F. Kadlubar, "Carcinogen substrate specificity of human COX-1 and COX-2," Carcinogenesis, vol. 22, no. 1, pp. 5–10, Jan. 2001, doi: 10.1093/carcin/22.1.5.
  4. M. E. Turini and R. N. DuBois, "Cyclooxygenase-2: A therapeutic target," Annu. Rev. Med., vol. 53, pp. 35–57, 2002, doi: 10.1146/annurev.med.53.082901.103952.
  5. P. L. McCormack, "Celecoxib: A review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis," Drugs, vol. 71, no. 18, pp. 2457–2489, Dec. 2011, doi: 10.2165/11208240-000000000-00000.
  6. K. L. Reckamp et al., "Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin," J. Thorac. Oncol., vol. 3, no. 2, pp. 117–124, Feb. 2008, doi: 10.1097/JTO.0b013e3181622bef.
  7. X. C. Xu, "COX-2 inhibitors in cancer treatment and prevention, a recent development," Anticancer Drugs, vol. 13, no. 2, pp. 127–137, Feb. 2002, doi: 10.1097/00001813-200202000-00003.
  8. M. D. Ferrer et al., "Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases," Curr. Med. Chem., vol. 26, no. 18, pp. 3225–3241, 2019, doi: 10.2174/0929867325666180514112124.
  9. R. S. Bresalier et al., "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial," N. Engl. J. Med., vol. 352, no. 11, pp. 1092–1102, Mar. 2005, doi: 10.1056/NEJMoa050493.
  10. L. G. Howes, "Selective COX-2 inhibitors, NSAIDs and cardiovascular events—is celecoxib the safest choice?," Ther. Clin. Risk Manag., vol. 3, no. 5, pp. 831–845, Oct. 2007.
  11. N. A. Nussmeier et al., "Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery," N. Engl. J. Med., vol. 352, no. 11, pp. 1081–1091, Mar. 2005, doi: 10.1056/NEJMoa050330.
  12. E. Ott et al., "Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery," J. Thorac. Cardiovasc. Surg., vol. 125, no. 6, pp. 1481–1492, Jun. 2003, doi: 10.1016/s0022-5223(03)00125-9.
  13. N. S. Kirkby et al., "Mechanistic definition of the cardiovascular mPGES-1/COX-2/ADMA axis," Cardiovasc. Res., vol. 116, no. 12, pp. 1972–1980, Oct. 2020, doi: 10.1093/cvr/cvz290.
  14. M. B. Forrester, "Human ingestions of veterinary cyclooxygenase-2 inhibitors," J. Pharm. Technol., vol. 26, no. 3, pp. 107–110, 2010, doi: 10.1177/875512251002600302.
  15. V. V. Tkach et al., "Theoretical description for firocoxib cathodic electrochemical determination in meat and milk," Lett. Appl. NanoBioScience, vol. 14, no. 4, pp. 1–7, 2025.
  16. A. Guzmán, J. Homedes, and M. Salichs, "Evaluation of the Genotoxic Potential of the Selective COX-2 Inhibitor Enflicoxib in a Battery of in vitro and in vivo Genotoxicity Assays," Drug Res. (Stuttg.), vol. 72, no. 3, pp. 163–170, Mar. 2022, doi: 10.1055/a-1727-5733.
  17. A. Attiq et al., "Augmented cytotoxic, mutagenic and genotoxic response triggered by carvedilol and celecoxib combinations," Braz. J. Pharm. Sci., vol. 54, no. 1, Art. no. e17292, 2018, doi: 10.1590/s2175-97902018000117292.
  18. A. Son et al., "Recent advances in omics, computational models, and advanced screening methods for drug safety and efficacy," Toxics, vol. 12, Art. no. 822, 2024, doi: 10.3390/toxics12110822.
  19. E. Benfenati, A. Manganaro, and G. Gini, "VEGA-QSAR: AI inside a platform for predictive toxicology," 2013. [Online]. Available: https://ceur-ws.org/Vol-1107/paper8.pdf. Accessed: Oct. 7, 2026.
  20. G. Patlewicz, N. Jeliazkova, R. J. Safford, A. P. Worth, and B. Aleksiev, "An evaluation of the implementation of the Cramer classification scheme in the Toxtree software," SAR QSAR Environ. Res., vol. 19, no. 5-6, pp. 495–524, 2008, doi: 10.1080/10629360802083871.
  21. G. M. Cramer, R. A. Ford, and R. L. Hall, "Estimation of toxic hazard—A decision tree approach," Food Cosmet. Toxicol., vol. 16, no. 3, pp. 255–276, 1976, doi: 10.1016/S0015-6264(76)80522-6.
  22. U.S. Environmental Protection Agency, "Toxicity estimation software tool (T.E.S.T.)," Feb. 2025. [Online]. Available: https://www.epa.gov/chemical-research/toxicity-estimation-software-tool-test. Accessed: Oct. 7, 2026.
  23. National Center for Biotechnology Information, "PubChem database," 2025. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov. Accessed: Oct. 7, 2026.
  24. N. Fjodorova, M. Vracko, M. Novic, A. Roncaglioni, and E. Benfenati, "New public QSAR model for carcinogenicity," Chem. Cent. J., vol. 4, no. Suppl 1, p. S3, Jul. 2010, doi: 10.1186/1752-153X-4-S1-S3.
  25. A. Cassano et al., "Evaluation of QSAR models for the prediction of Ames genotoxicity: a retrospective exercise on the chemical substances registered under the EU REACH regulation," J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev., vol. 32, no. 3, pp. 273–298, 2014, doi: 10.1080/10590501.2014.938955.
  26. A. A. Toropov, A. P. Toropova, G. Raitano, and E. Benfenati, "CORAL: Building up QSAR models for the chromosome aberration test," Saudi J. Biol. Sci., vol. 26, no. 6, pp. 1101–1106, Sep. 2019, doi: 10.1016/j.sjbs.2018.05.013.
  27. D. Baderna et al., "New in silico models to predict in vitro micronucleus induction as marker of genotoxicity," J. Hazard. Mater., vol. 385, Art. no. 121638, Mar. 2020, doi: 10.1016/j.jhazmat.2019.121638.
  28. M. Van Bossuyt et al., "New QSAR models to predict chromosome damaging potential based on the in vivo micronucleus test," Toxicol. Lett., vol. 329, pp. 80–84, Sep. 2020, doi: 10.1016/j.toxlet.2020.04.016.
  29. F. Pizzo, A. Lombardo, A. Manganaro, and E. Benfenati, "A new structure-activity relationship (SAR) model for predicting drug-induced liver injury, based on statistical and expert-based structural alerts," Front. Pharmacol., vol. 7, p. 442, Nov. 2016, doi: 10.3389/fphar.2016.00442.
  30. R. Benigni, C. Bossa, N. Jeliazkova, T. Netzeva, and A. Worth, "The Benigni/Bossa rulebase for mutagenicity and carcinogenicity—a module of Toxtree," EUR 23241 EN, 2008. [Online]. Available: https://publications.jrc.ec.europa.eu/repository/handle/JRC43157. Accessed: Oct. 7, 2026.
  31. R. Benigni and C. Bossa, "Mechanisms of chemical carcinogenicity and mutagenicity: A review with implications for predictive toxicology," Chem. Rev., vol. 111, no. 4, pp. 2507–2536, Apr. 2011, doi: 10.1021/cr100222q.
  32. R. Benigni, C. Bossa, O. Tcheremenskaia, and A. Worth, "Development of structural alerts for the in vivo micronucleus assay in rodents," EUR 23844 EN, 2009. [Online]. Available: https://publications.jrc.ec.europa.eu/repository/handle/JRC52274. Accessed: Oct. 7, 2026.
  33. U.S. Environmental Protection Agency, "User’s guide for T.E.S.T. (version 5.1) (Toxicity Estimation Software Tool): a program to estimate toxicity from molecular structure," Washington, DC, 2020. [Online]. Available: https://www.epa.gov/sites/default/files/2016-05/documents/600r16058.pdf. Accessed: Oct. 7, 2026.
  34. S. Raju et al., "Identification of novel fructose 1,6-bisphosphate aldolase inhibitors against tuberculosis: QSAR, molecular docking, and molecular dynamics simulation-based analysis of DrugBank compounds," J. Biomol. Struct. Dyn., vol. 43, no. 15, pp. 8734–8747, Sep. 2025, doi: 10.1080/07391102.2024.2436552.
  35. P. Gumułka et al., "Comprehensive assessment of the stability of selected coxibs in variable environmental conditions along with the assessment of their potential hepatotoxicity," Pharmaceutics, vol. 15, no. 11, Art. no. 2609, Nov. 2023, doi: 10.3390/pharmaceutics15112609.
  36. C. Matthias, M. T. Schuster, S. Zieger, and U. Harréus, "COX-2 inhibitors celecoxib and rofecoxib prevent oxidative DNA fragmentation," Anticancer Res., vol. 26, no. 3A, pp. 2003–2007, May 2006.
  37. S. J. Hosseinimehr, M. Fathi, A. Ghasemi, S. N. Shiadeh, and T. A. Pourfallah, "Celecoxib mitigates genotoxicity induced by ionizing radiation in human blood lymphocytes," Res. Pharm. Sci., vol. 12, no. 1, pp. 82–87, Feb. 2017, doi: 10.4103/1735-5362.199051.
  38. H. Reimann, Q. A. Ngo, H. Stopper, and H. Hintzsche, "Cytokinesis-block micronucleus assay of celecoxib and celecoxib derivatives," Toxicol. Rep., vol. 7, pp. 1588–1591, Nov. 2020, doi: 10.1016/j.toxrep.2020.11.004.
  39. I. I. El Hajj, S. M. Malik, H. R. Alwakeel, O. S. Shaikh, E. Sasatomi, and H. M. Kandil, "Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation," World J. Gastroenterol., vol. 15, no. 31, pp. 3937–3939, Aug. 2009, doi: 10.3748/wjg.15.3937.
  40. P. Soni, B. Shell, G. Cawkwell, C. Li, and H. Ma, "The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: Pooled analysis of 41 randomized controlled trials," Curr. Med. Res. Opin., vol. 25, no. 8, pp. 1841–1851, Aug. 2009, doi: 10.1185/03007990903018279.
  41. W. C. Maddrey, C. J. Maurath, K. M. Verburg, and G. S. Geis, "The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib," Am. J. Ther., vol. 7, no. 3, pp. 153–158, May 2000, doi: 10.1097/00045391-200007030-00003.
  42. D. J. Cochrane, B. Jarvis, and G. M. Keating, "Etoricoxib," Drugs, vol. 62, no. 18, pp. 2637–2651, 2002, doi: 10.2165/00003495-200262180-00006.
  43. R. K. Saini, S. N. Sanyal, and J. S. Bhatti, "Chemopreventive action of non-steroidal anti-inflammatory drugs in 9,10-dimethylbenzanthracene induced lung carcinogenesis in BALB/C mice: expression of COX-1, COX-2 and Nf-κB," J. Appl. Biomed., vol. 16, no. 4, pp. 320–327, 2018, doi: 10.1016/j.jab.2018.03.002.
  44. V. Baty et al., "Hépatite imputable à l'alpidem (Ananxyl). Quatre cas dont un mortel [Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal]," Gastroenterol. Clin. Biol., vol. 18, no. 12, pp. 1129–1131, 1994.
  45. K. A. Lyseng-Williamson and M. P. Curran, "Lumiracoxib," Drugs, vol. 64, no. 19, pp. 2237–2246, 2004, doi: 10.2165/00003495-200464190-00008.
  46. P. I. Pillans, R. A. Ghiculescu, G. Lampe, R. Wilson, R. Wong, and G. A. Macdonald, "Severe acute liver injury associated with lumiracoxib," J. Gastroenterol. Hepatol., vol. 27, no. 6, pp. 1102–1105, Jun. 2012, doi: 10.1111/j.1440-1746.2011.07036.x.
  47. J. B. Singer et al., "A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury," Nat. Genet., vol. 42, no. 8, pp. 711–714, Aug. 2010, doi: 10.1038/ng.632.
  48. IARC, "4,4'-Methylene bis(2-methylaniline)," in IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 4, Suppl. 7, Lyon: IARC, 1987, p. 248.
  49. A. J. Vecchio and M. G. Malkowski, "The structure of NS-398 bound to cyclooxygenase-2," J. Struct. Biol., vol. 176, no. 2, pp. 254–258, Nov. 2011, doi: 10.1016/j.jsb.2011.07.019.
  50. E. M. Choi et al., "COX-2 regulates p53 activity and inhibits DNA damage-induced apoptosis," Biochem. Biophys. Res. Commun., vol. 328, no. 4, pp. 1107–1112, Mar. 2005, doi: 10.1016/j.bbrc.2005.01.072.
  51. P. Kovacic and R. Somanathan, "Nitroaromatic compounds: Environmental toxicity, carcinogenicity, mutagenicity, therapy and mechanism," J. Appl. Toxicol., vol. 34, no. 8, pp. 810–824, Aug. 2014, doi: 10.1002/jat.2980.
  52. S. L. Walker, F. Kennedy, N. Niamh, and P. A. McCormick, "Nimesulide associated fulminant hepatic failure," Pharmacoepidemiol. Drug Saf., vol. 17, no. 11, pp. 1108–1112, Nov. 2008, doi: 10.1002/pds.1665.
  53. European Medicines Agency, "Questions and answers on the review of systemic medicines containing nimesulide," Jan. 2012. [Online]. Available: https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_en.pdf. Accessed: Oct. 7, 2026.
  54. G. A. FitzGerald, "Coxibs and cardiovascular disease," N. Engl. J. Med., vol. 351, no. 17, pp. 1709–1711, Oct. 2004, doi: 10.1056/NEJMp048288.
  55. European Medicines Agency, "Dynastat (parecoxib) EMEA/CPMP/1166/02/2004 scientific discussion," 2004. [Online]. Available: https://www.ema.europa.eu/en/documents/scientific-discussion/dynastat-epar-scientific-discussion_en.pdf. Accessed: Oct. 7, 2026.
  56. T. Zhang, Y. Ma, K. Q. Xu, and W. Q. Huang, "Pretreatment of parecoxib attenuates hepatic ischemia/reperfusion injury in rats," BMC Anesthesiol., vol. 15, Art. no. 165, Nov. 2015, doi: 10.1186/s12871-015-0147-0.
  57. S. Hirankarn, J. S. Barrett, N. Alamuddin, G. A. FitzGerald, and C. Skarke, "GCG100649, a novel cyclooxygenase-2 inhibitor, exhibits a drug disposition profile in healthy volunteers compatible with high affinity to carbonic anhydrase-I/II: preliminary dose-exposure relationships to define clinical development strategies," Clin. Pharmacol. Drug Dev., vol. 2, no. 4, pp. 379–386, Oct. 2013, doi: 10.1002/cpdd.47.
  58. W. K. Schmidt et al., "324 CG100649, a tissue-specific dual inhibitor of COX-2 and carbonic anhydrase: phase 2A clinical trial in hip & knee osteoarthritis," Osteoarthritis Cartilage, vol. 17, no. Suppl 1, p. S173, 2009, doi: 10.1016/S1063-4584(09)60346-0.
  59. R. Easwaran, U. K. Mistry, M. Bhole, and K. Peethambaran, "Polmacoxib: A review of the newer non-steroidal drug in osteoarthritis," Cureus, vol. 16, no. 4, Art. no. e58446, Apr. 2024, doi: 10.7759/cureus.58446.
  60. J. K. Reddy, D. L. Azarnoff, and C. E. Hignite, "Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens," Nature, vol. 283, no. 5745, pp. 397–398, Jan. 1980, doi: 10.1038/283397a0.
  61. National Institute of Diabetes and Digestive and Kidney Diseases, "Rofecoxib," in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, 2012. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK548628/. Accessed: Oct. 7, 2026.
  62. J. S. Ross and H. M. Krumholz, "Bringing Vioxx back to market," BMJ, vol. 360, Art. no. k242, Jan. 2018, doi: 10.1136/bmj.k242.
  63. Thomson PDR, Physicians' Desk Reference, 58th ed., Montvale, NJ, USA: Thomson PDR, 2004, p. 2111.
  64. D. Sanchez-Matienzo, A. Arana, J. Castellsague, and S. Perez-Gutthann, "Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of spontaneous reports," Clin. Ther., vol. 28, no. 8, pp. 1123–1132, Aug. 2006, doi: 10.1016/j.clinthera.2006.08.014.
  65. B. Yan, Y. Leung, S. J. Urbanski, and R. P. Myers, "Rofecoxib-induced hepatotoxicity: A forgotten complication of the coxibs," Can. J. Gastroenterol., vol. 20, no. 5, pp. 351–355, May 2006, doi: 10.1155/2006/356434.
  66. T. Fujimura, T. Ohta, K. Oyama, T. Miyashita, and K. Miwa, "Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: A review and report of personal experience," World J. Gastroenterol., vol. 12, no. 9, pp. 1336–1345, Mar. 2006, doi: 10.3748/wjg.v12.i9.1336.
  67. T. Nagahara, J. Okano, Y. Fujise, R. Abe, and Y. Murawaki, "Preventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on DEN-induced hepatocarcinogenesis in rats," Biomed. Pharmacother., vol. 64, no. 5, pp. 319–326, May 2010, doi: 10.1016/j.biopha.2009.09.023.
  68. N. L. Nakao, A. M. Gelb, R. J. Stenger, and J. H. Siegel, "A case of chronic liver disease due to tolazamide," Gastroenterology, vol. 89, no. 1, pp. 192–195, Jul. 1985, doi: 10.1016/0016-5085(85)90762-0.
  69. B. Birmingham and A. Buvanendran, "Nonsteroidal anti-inflammatory drugs, acetaminophen, and COX-2 inhibitors," in Practical Management of Pain, 5th ed., H. T. Benzon, J. P. Rathmell, C. L. Wu, D. C. Turk, C. E. Argoff, and R. W. Hurley, Eds., Philadelphia, PA, USA: Mosby, 2014, pp. 553–568.e5, doi: 10.1016/B978-0-323-08340-9.00040-2.
  70. U.S. FDA Center for Drug Evaluation and Research, "Bextra (valdecoxib tablets)—application number 21-341," Nov. 2001. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_prntlbl.pdf. Accessed: Oct. 7, 2026.
  71. N. Chalasani et al., "Features and outcomes of 899 patients with drug- induced liver injury: The DILIN prospective study," Gastroenterology, vol. 148, no. 7, pp. 1340–1352.e7, Jun. 2015, doi: 10.1053/j.gastro.2015.03.006.
  72. J. J. Yang et al., "Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: Incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia," PLoS One, vol. 9, no. 9, p. e106141, Sep. 2014, doi: 10.1371/journal.pone.0106141.
  73. S. J. Rizvi and S. H. Kennedy, "Emerging drugs for major depressive disorder: An update," Expert Opin. Emerg. Drugs, vol. 17, no. 3, pp. 285–294, 2012, doi: 10.1517/14728214.2012.681301.
  74. Australian Government, Department of Health and Aged Care, "2.4. Cimicoxib," Feb. 2018. [Online]. Available: https://www.tga.gov.au/resources/publication/scheduling-decisions-interim/scheduling-delegates-interim-decisions-and-invitation-further-comment-accsacms-november-2017/24-cimicoxib. Accessed: Oct. 7, 2026.
  75. European Medicines Agency, "Cimalgex (cimicoxib) EMA/CVMP/513842/2011 scientific discussion," 2011. [Online]. Available: https://medicines.health.europa.eu/veterinary/pl/documents/download/2709be52-f857-4a76-9b5c-1ee7c01dd335. Accessed: Oct. 7, 2026.
  76. National Center for Biotechnology Information, "PubChem compound summary for CID 213053, cimicoxib," 2025. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/Cimicoxib. Accessed: Oct. 7, 2026.
  77. S. Budsberg, "Nonsteroidal anti-inflammatory drugs," in Handbook of Veterinary Pain Management, St. Louis, MO, USA: Mosby, 2002, pp. 184–195.
  78. E. S. Roberts, K. A. Van Lare, B. R. Marable, and W. F. Salminen, "Safety and tolerability of 3-week and 6-month dosing of Deramaxx® (deracoxib) chewable tablets in dogs," J. Vet. Pharmacol. Ther., vol. 32, no. 4, pp. 329–337, Aug. 2009, doi: 10.1111/j.1365-2885.2008.01043.x.
  79. European Medicines Agency, "Daxocox, enflicoxib. European public assessment reports (EPAR)," 2023. [Online]. Available: https://ec.europa.eu/health/documents/community-register/2023/20230516159019/anx_159019_en.pdf. Accessed: Oct. 7, 2026.
  80. J. Homedes, M. Salichs, and A. Guzman, "Long-term safety evaluation of Daxocox® tablets (enflicoxib) in dogs after weekly oral administrations for seven months," BMC Vet. Res., vol. 17, no. 1, Art. no. 205, Jun. 2021, doi: 10.1186/s12917-021-02910-0.
  81. U.S. Food and Drug Administration, "FDA approves the first generic firocoxib tablets for horses," 2022. [Online]. Available: https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-firocoxib-tablets-horses. Accessed: Oct. 7, 2026.
  82. European Medicines Agency, "Previcox (firocoxib) EMEA/CVMP/86256/2007 scientific discussion," 2007. [Online]. Available: https://ec.europa.eu/health/documents/community-register/2011/20110518102788/anx_102788_en.pdf. Accessed: Oct. 7, 2026.
  83. P. V. Steagall, F. B. Mantovani, T. H. Ferreira, E. S. Salcedo, F. Q. Moutinho, and S. P. Luna, "Evaluation of the adverse effects of oral firocoxib in healthy dogs," J. Vet. Pharmacol. Ther., vol. 30, no. 3, pp. 218–223, Jun. 2007, doi: 10.1111/j.1365-2885.2007.00842.x.
  84. P. Lees, L. Pelligand, J. Elliott, P. L. Toutain, G. Michels, and M. Stegemann, "Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: A review," J. Vet. Pharmacol. Ther., vol. 38, no. 1, pp. 1–14, Feb. 2015, doi: 10.1111/jvp.12185.
  85. G. L. Huckins, J. W. Carpenter, S. Dias, and B. KuKanich, "Pharmacokinetics of oral mavacoxib in Caribbean flamingos (Phoenicopterus ruber ruber)," J. Zoo Wildl. Med., vol. 51, no. 1, pp. 53–58, 2020.
  86. European Medicines Agency, "Onsior, INN-robenacoxib. European public assessment reports (EPAR)," 2023. [Online]. Available: https://ec.europa.eu/health/documents/community-register/2023/20230608159327/anx_159327_en.pdf. Accessed: Oct. 7, 2026.
  87. Z. Özdemir Kütahya and P. Piner Benli, "The effect of oral administration of robenacoxib on hematological and biochemical parameters in different goat breeds," Vet. J. Mehmet Akif Ersoy Univ., vol. 8, no. 3, pp. 206–211, 2023, doi: 10.24880/maeuvfd.1347911.
  88. European Medicines Agency, "Onsior (robenacoxib) EMEA/CVMP/564644/2008 scientific discussion," Dec. 2008. [Online]. Available: https://medicines.health.europa.eu/veterinary/et/documents/download/98e1b462-ca6f-4b92-9c4a-2689b455696f. Accessed: Oct. 7, 2026.
  89. J. Pena-Ramos, N. C. Finch, and S. Sanchez-Redondo, "Suspected robenacoxib-induced liver injury in a dog," Vet. Rec. Case Rep., vol. 11, Art. no. e704, 2023, doi: 10.1002/vrc2.704.
  90. M. Fink et al., "Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis," Res. Vet. Sci., vol. 95, no. 2, pp. 580–587, Oct. 2013, doi: 10.1016/j.rvsc.2013.04.021.
  91. J. Wang et al., "Determination of vitacoxib, a novel COX-2 inhibitor, in equine plasma using UPLC-MS/MS detection: Development and validation of new methodology," J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., vol. 1061–1062, pp. 270–274, Sep. 2017, doi: 10.1016/j.jchromb.2017.07.024.
  92. H. K. Knych, S. D. Stanley, R. M. Arthur, and M. M. Mitchell, "Detection and pharmacokinetics of three formulations of firocoxib following multiple administrations to horses," Equine Vet. J., vol. 46, no. 6, pp. 734–738, Nov. 2014, doi: 10.1111/evj.12211.
  93. J. Wang, F. Sun, S. Tang, S. Zhang, J. Li, and X. Cao, "Mutagenicity and teratogenicity studies of vitacoxib in rats and mice," Toxicol. Rep., vol. 5, pp. 827–831, Aug. 2018, doi: 10.1016/j.toxrep.2018.08.007.
  94. J. Wang, T. Zhao, S. Tang, S. Zhang, P. Lv, J. Li, and X. Cao, "Safety assessment of vitacoxib: 180-day chronic oral toxicity studies," Regul. Toxicol. Pharmacol., vol. 95, pp. 244–249, Jun. 2018, doi: 10.1016/j.yrtph.2018.03.024.
  95. A. J. Hui, R. W. Leong, and F. K. L. Chan, "Gastric Ulcer," in Encyclopedia of Gastroenterology, L. R. Johnson, Ed., New York, NY, USA: Elsevier, pp. 157–162, 2004. doi:10.1016/B0-12-386860-2/00311-7.